VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
Apple Inc. vs Bio-Rad Laboratories, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Apple Inc.
AAPL · NASDAQ
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Bio-Rad Laboratories, Inc.
BIO · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bio-Rad Laboratories, Inc.'s moat claims, evidence, and risks.
View BIO analysisComparison highlights
- Moat score gap: Apple Inc. leads (87 / 100 vs 61 / 100 for Bio-Rad Laboratories, Inc.).
- Segment focus: Apple Inc. has 5 segments (50.4% in iPhone); Bio-Rad Laboratories, Inc. has 2 segments (59.9% in Clinical Diagnostics).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: Apple Inc. has 7 moat types across 3 domains; Bio-Rad Laboratories, Inc. has 6 across 3.
Primary market context
Apple Inc.
iPhone
Smartphones (with focus on premium smartphones and iOS ecosystem devices)
Global
Consumers and enterprises (end-users), plus carrier/retail channels
OEM / platform owner
50.4%
Bio-Rad Laboratories, Inc.
Clinical Diagnostics
In vitro diagnostics test systems, reagents/test kits, informatics, and clinical laboratory quality controls
Global
Hospital laboratories; diagnostic reference laboratories; transfusion laboratories; physician office laboratories
IVD OEM / installed-base consumables supplier (systems + kits + controls)
59.9%
Side-by-side metrics
Moat coverage
Shared moat types
Apple Inc. strengths
Bio-Rad Laboratories, Inc. strengths
Segment mix
Apple Inc. segments
Full profile >iPhone
Oligopoly
Mac
Oligopoly
iPad
Oligopoly
Wearables, Home and Accessories
Competitive
Services
Quasi-Monopoly
Bio-Rad Laboratories, Inc. segments
Full profile >Life Science
Competitive
Clinical Diagnostics
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.